Showing results (191-200 of 330) with videos related to

Sort By:
Pageof 33
Anticancer Research|August 28, 2024
Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular CarcinomaNobuharu Tamaki, Nami Mori, Shintaro Takaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 30, 2021
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control studyMargherita Rimini, Shigeo Shimose, Sara Lonardi, et al.
Investigational New Drugs|March 30, 2023
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study GroupShintaro Takaki, Masayuki Kurosaki, Nami Mori, et al.
Journal of Gastroenterology|February 24, 2025
Diagnostic performance of attenuation imaging versus controlled attenuation parameter for hepatic steatosis with MRI-based proton density fat fraction as the reference standard: a prospective multicenter studyTakashi Nishimura, Toshifumi Tada, Tomoyuki Akita, et al.
Hepatology International|July 4, 2024
Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinomaMakoto Chuma, Haruki Uojima, Hidenori Toyoda, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 6, 2026
The Hepatic Steatosis Diagnostic Performance Using Attenuation Imaging With the Magnetic Resonance Imaging-Based Proton Density Fat Fraction as the Reference Standard: A Large, Prospective, Multicenter Cohort Study in JapanTakashi Nishimura, Hiroko Iijima, Yasuaki Suzuki, et al.
Journal of Gastroenterology and Hepatology|January 31, 2024
Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinomaHidenori Toyoda, Toshifumi Tada, Haruki Uojima, et al.
Oncology|August 30, 2019
Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, et al.
Journal of Gastroenterology and Hepatology|July 12, 2018
Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysisAtsushi Hiraoka, Takashi Kumada, Chikara Ogawa, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 30, 2019
Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matchingToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Pageof 33